Supported projects

T202003 – Pre-clinical model for the use of universal MAIT cells carrying a chimeric receptor (CAR-MAIT)

Scientific leader
Dr. Sophie Caillat-Zucman

The success of clinical trials using T cells carrying a chimeric receptor (CAR-T) has demonstrated the fantastic potential of this strategy in malignant hemopathies. However, the CAR-T must be produced individually on demand for each patient, which poses logistical difficulties and has a prohibitive cost for wider use. Our goal is to produce so-called “universal” cells, ready to use for any patient, using Mucosal-associated invariant T (MAIT) cells. We produced CD19-CAR MAIT as proof of concept, and demonstrated their ability to eliminate CD19+ leukemia target cells in vitro. Our research program aims to confirm the anti-tumor efficacy of CD19‐CAR MAIT in vivo and to verify their absence of toxicity in a pre-clinical model (immunodeficient NSG mice), before considering a clinical trial.





UMR976/ équipe INSIGHT

Hôpital St-Louis, Bâtiment Hayem

1 avenue Claude Vellefaux

75 010 Paris